manassas semaglutide & tirzepatide FDA Grants a New Indication for Obesity Management Hospira brand 30ml Bacteriostatic limit-4 Select your plan & weekly dose:30-Day · 7mg · $379

manassas semaglutide & tirzepatide FDA Grants a New Indication for Obesity Management Hospira brand 30ml Bacteriostatic limit-4 Select your plan & weekly dose:30-Day · 7mg · $379

Hospira brand 30ml Bacteriostatic Sterile Water for Injection

Obesity characteristics are poor predictors of genetic mutations associated with obesity

limit-4

Select your plan & weekly dose:30-Day · 7mg · $379

The STEP (Semaglutide Treatment Effect in People with obesity) trials, which included over 4,500 participants, showed that semaglutide 2.4 mg weekly resulted in mean weight loss of 12.4% to 15.3% of initial body weight over 68 weeks, compared to 2.4% to 3.2% with placebo